Gilead Sciences (GILD) should not see any impact from the reported cost reductions at the US Department of Health and Human Services, Truist said in a note Wednesday.
The reported changes in the financial overhaul, which appear to be targeting the HIV portion of the prevention efforts, are not expected to affect HIV drug reimbursement or national coverage, the investment firm said.
The Department of Health and Human Services is considering major reductions to funding for domestic HIV prevention efforts, though a final decision has not been made, the Wall Street Journal reported late Tuesday, citing sources with knowledge of the matter.
These potential cuts may be announced within a day and come amid a broader reorganization at the Centers for Disease Control and Prevention, the meda outlet had reported.
The CDC spent about $1.3 billion in the 2023 fiscal year on preventing HIV, viral hepatitis, sexually transmitted infections, and tuberculosis, with most of that money awarded through grants and cooperative agreements, the WSJ reported, citing the CDC.
The US Department of Health and Human Services and CDC did not immediately respond to requests for a comment from MT Newswires.
Shares of the company were down about 3.1% in recent trading.
Truist maintained a hold rating for Gilead Sciences with a $97 price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。